Jan. 20, 2023 Price forecast | 2 weeks: -2.04% | 1 month: -5.46% | 3 months: -14.24%


MRTX stock forecast

Our latest prediction for Mirati Therapeutics Inc's stock price was made on the Jan. 20, 2023 when the stock price was at 45.66$.

In the short term (2weeks), MRTX's stock price should underperform the market by -2.04%. During that period the price should oscillate between -9.49% and +7.57%.

In the medium term (3months), MRTX's stock price should underperform the market by -14.24%. During that period the price should oscillate between -28.09% and +18.70%.

Create a solid portfolio with MRTX

Add MRTX to your portfolio and optimize it!


About Mirati Therapeutics Inc

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Mirati is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, and other oncology discovery programs. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

At the moment the company generates 702M USD in revenues.

On its last earning announcement, the company reported a loss of -11.22$ per share.

The book value per share is 7.61$

Mirati Therapeutics Inc website


Three months stock forecastJan. 20, 2023


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
702M 1.67% -744M -105.97% -738M -11.22 - - 57M 7.61 - - -